Reset filter
Keywords
Hematology ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
    1. 1.1. Eligibility Determination
    1. 1.2. Medical History
    1. 1.3. Physical Examination
    1. 1.4. Assessment Score
    1. 1.5. Apparative Diagnostics
    1. 1.6. Laboratory
    1. 1.7. Pathology/Histology
    1. 1.8. Consent
    1. 1.9. Therapy
    1. 1.10. Operative Report
    1. 1.11. Adverse Event
    1. 1.12. Follow-Up
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

626 Search results.
Relevance Rating New first Old first

Eligibility Lymphoma NCT00290498

- 9/27/21 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Rituximab-HCVAD in Patients With B-Cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00290498

Eligibility Mature B-Cell Lymphoma NCT01046825

- 9/27/21 - 1 form, 2 itemgroups, 25 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Mature B-Cell Lymphoma And Leukemia Study III; ODM derived from: https://clinicaltrials.gov/show/NCT01046825

Eligibility Lymphoma, Large-Cell, Anaplastic NCT00866047

- 9/20/21 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00866047

Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma NCT00920556 - Screening - Demography; Inclusion Criteria; Exclusion Criteria

- 9/20/21 - 1 form, 4 itemgroups, 34 items, 1 language
Itemgroups: Administrative, Demography, Inclusion Criteria, Exclusion Criteria
Study ID: 113222 Clinical Study ID: 113222 Study Title: A Phase II, Open Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00920556 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name:5.0g SRT501 Trade Name: Bortezomib Study Indication: Multiple Myeloma

Eligibility Lymphoma NCT02056548

- 9/20/21 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy; ODM derived from: https://clinicaltrials.gov/show/NCT02056548

Eligibility Lymphoma NCT02392039

- 9/20/21 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02392039

Eligibility Multiple Myeloma NCT00642395

- 9/20/21 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT); ODM derived from: https://clinicaltrials.gov/show/NCT00642395

Eligibility Multiple Myeloma NCT00590603

- 9/20/21 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00590603

Eligibility Multiple Myeloma NCT00086216

- 9/20/21 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00086216

Eligibility Lymphoma NCT00275106

- 9/20/21 - 1 form, 1 itemgroup, 18 items, 1 language
Itemgroup: Criteria
Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00275106

Eligibility Lymphoma NCT00290433

- 9/20/21 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00290433

Eligibility Chronic Lymphocytic Leukemia NCT00286780

- 9/20/21 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00286780

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial